Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to $214 million to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.

BARDA, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), will initially invest approximately $35 million to produce up to 100,000 doses of Sabin’s Ebola Sudan virus (ChAd3-SUDV) vaccine. These vaccines may be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.

The Sabin vaccine was the first to arrive in Uganda during the recent Ebola Sudan virus outbreak that caused 55 deaths after the World Health Organization included it as one of three vaccines for possible use in an outbreak trial in Uganda. The country declared the Ebola Sudan outbreak had ended on January 11, four months after the first confirmed case.

“Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment,” says Sabin Chief Executive Officer Amy Finan. “This new contract enables Sabin to produce up to 100,000 doses so the world is prepared in advance for future outbreaks.”

In addition to participating in recent outbreak activities, Sabin continues its Sudan development plan and has initiated Phase 2 clinical trial planning in Uganda and Kenya. Based on previous clinical trials, Sabin’s Ebola Sudan vaccine is safe and immunogenic, and in nonhuman primate studies has demonstrated rapid protection, durability up to 12 months, and efficacy.

In addition to Sabin’s ChAd3-SUDV vaccine, the contract also includes support to manufacture Sabin’s vaccine against Marburg virus (ChAd3-MARV), which would generate doses that could also be used in trials and in response to a possible Marburg virus outbreak. As recently as last July, two people in Ghana died after being infected with Marburg virus, reinforcing the urgent need for a vaccine.

The new contract leverages a partnership with BARDA that began in 2019, when the agency awarded Sabin another multi-year contract valued at $128 million to further the development of vaccines against both the Marburg and Ebola Sudan viruses.

“BARDA has been a supportive partner as we take these essential steps in pandemic preparedness,” said Finan. “The Ebola Sudan outbreak in Uganda underscored the critical need for readily available solutions. We’ll now have ample material to respond quickly to such an outbreak in the future.”

This project will be funded in whole with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50123C00010.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

About Ebola Sudan and Marburg

Ebola Sudan and Marburg are members of the filovirus family. Both can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of these hemorrhagic fevers has been licensed to date. Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control.

Marburg was the first filovirus to be recognized in 1967 when outbreaks of hemorrhagic fever were reported in a few Europe-based laboratories including in the town of Marburg, Germany. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and in southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered.

For media inquiries:

press@sabin.org

Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662-1841
press@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/539c9127-e5d6-4b32-9e89-780f7461314b


Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

THỦ THUẬT HAY

Cài đặt tinh chỉnh FullScreenX cho các game và ứng dụng chưa hỗ trợ trên iPhone X

Về cơ bản, tweak này sẽ nhân đôi những khoảng trống trong thiết kế của ứng dụng, nhằm kéo dài giao diện cho phù hợp với tỉ lệ khung hình và nâng cao khả năng hiển thị trên iPhone X. Để tải về FullScreenX, bạn cần thực

Cách tra cứu kết quả đóng BHXH, BHYT, BHTN

Giờ đây, chỉ cần có kết nối mạng Internet bạn có thể tra cứu mã số bảo hiểm xã hội (BHXH), quá trình tham gia BHXH trực tuyến vô cùng nhanh chóng, mà không phải tốn công lên cơ quan BHXH như trước đây nữa.

Cách bỏ thích Fanpage Facebook hàng loạt đơn giản, ai cũng làm được

Hướng dẫn bạn cách bỏ thích hàng loạt Fanpage Facebook trên điện thoại, máy tính để tránh phải đọc những bài viết từ các trang mà bạn chưa bao giờ theo dõi đến. Click xem ngay nhé!

Hướng dẫn trải nghiệm âm thanh 3D với tai nghe trên Windows 10

Âm thanh vòm (surround) là hệ thống âm thanh phát ra từ nhiều hướng bao quanh người nghe, tạo thành một vòm âm thanh và làm cho người nghe có cảm giác âm thanh khá chân thực. Các âm thanh này cho người nghe trải nghiệm

Cách thay đổi trình duyệt mặc định trên Windows 10

Microsoft Edge là trình duyệt mặc định trên Windows 10, tuy nhiên bạn hoàn toàn có thể đổi sang Google Chrome hay Mozilla Firefox nếu muốn.

ĐÁNH GIÁ NHANH

Cùng xem cuộc so găng giữa Canon 77D và Nikon D7500

77D – sản phẩm có số serie rất đặc biệt của Canon đang được đưa lên bàn cân để so sánh với chiếc máy mới ra mắt của Nikon là D7500. Xét về phân khúc thì cả hai đều thuộc dòng semi-pro trong khi thời gian ra mắt cũng

Đánh giá GoldTV SE1 - Bluetooth: dàn loa cho TV, smartphone

Đây là mẫu sản phẩm mới nhất của công ty loa GoldSound. Có thể thấy GoldSound tích cực ra mắt nhiều mẫu mã và chủng loại. Trong vòng vài tháng trở lại đây, công ty này đã ra mắt...

Đánh giá nhanh tai nghe không dây Samsung Gear IconX

Ra mắt trước Apple Airpod đến tận 2 tháng, Gear IconX thuộc dòng phụ kiện Gear của Samsung và là đối thủ ngang sức với thế hệ tai nghe không dây...